Clinical trials: Polycystic Kidney Disease
Autosomal Dominant Polycystic Kidney, ADPKD
Analysis of Patients With Autosomal Dominant Polycystic Kidney
The main objective of the study is to establish a database of clinical data and genetic data of patients diagnosed with ADPKD, with particular focus on those who have undertaken a specific therapy (Tolvaptan or Octreotide)…
- Trial name
- NCT06759142
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Autosomal Dominant Polycystic Kidney Disease, Disease Progression
Efficacy Study of Water Drinking on PKD Progression.
This is a prospective 5-year study to compare the change in total kidney volume (TKV) before and after tolvaptan therapy, as the primary endpoint, in patients with ADPKD.
- Trial name
- ESWP (NCT01348035)
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Kyorin University
Polycystic Kidney, Autosomal Dominant
The Role of Endothelial Dysfunction in Adult Polycystic Kidney Disease
This pilot study will compare endothelial function in patients with ADPKD with matched healthy volunteers and normotensive chronic kidney disease stage 1 \& 2 patients.
- Trial name
- NCT04023214
- Testing
- Peripheral (digital) arterial tonometry
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Autosomal Dominant Polycystic Kidney Disease
Autosomal Dominant Polycystic Kidney Disease Somatic Mutation Biorepository
This study will analyze the germline and somatic mutations underlying the development of ADPKD in order to better understand the genetic mechanism responsible for the cystic transformation.
- Trial name
- ADPKD (NCT03901521)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Weill Medical College of Cornell University
Adult Polycystic Kidney Disease
Renal Sympathetic Denervation for Reduction of Pain and Improvement of Insulin Sensitivity in Adult Polycystic Kidney Disease
In patients with polycystic kidney disease, pain may be resistant to drug therapy and may reduce quality of life. This study investigate the effect of renal denervation on this pain.
- Trial name
- NCT02062671
- Testing
- renal denervation
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Odense University Hospital
Autosomal Dominant Polycystic Kidney Disease
NOX4 and Related Biomarkers in ADPKD
To determine the value of NOX4, markers of mitochondria injury and function, and oxidative stress as real-time biomarkers to assess disease severity in patients with early autosomal dominant polycystic kidney disease (ADPKD).
- Trial name
- NCT04630613
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in ADPKD
The aim of this study is to identify families with ADPKD , characterize the phenotype and screen for mutations in known genes (PKD1 and PKD2, and then HNF1b and UMOD in PKD1 PKD2 negative carriers).
- Trial name
- GeneQuest (NCT02112136)
- Testing
- Blood Collection
- Where
- 25 sites in France
- Volunteers
- 1,450 people
- Sponsor
- University Hospital, Brest
ADPKD (Autosomal Dominant Polycystic Kidney Disease)
The German ADPKD Tolvaptan Treatment Registry
The German ADPKD Tolvaptan Treatment Registry is a prospective, observational, multicentric study of patients suffering from ADPKD that are considered for tolvaptan treatment.
- Trial name
- AD(H)PKD (NCT02497521)
- Where
- 12 sites in Germany
- Volunteers
- 2,000 people
- Sponsor
- University of Cologne
Autosomal Dominant Polycystic Kidney, ADPKD
Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD
The goal of the study was to compare and evaluate safety and efficacy of tesevatinib 50 milligrams (mg) versus placebo in participants with autosomal dominant polycystic kidney disease (ADPKD).
- Trial name
- NCT03203642
- Testing
- Tesevatinib
- Where
- 19 sites in United States
- Volunteers
- 80 people
- Sponsor
- Kadmon, a Sanofi Company
Healthy Volunteers
A Study of RGLS8429 in Healthy Volunteers
Primary Objective To assess the safety and tolerability of single ascending doses of RGLS8429 Secondary Objectives To identify dose-limiting toxicity (DLT) and to determine the maximum tolerated dose (MTD) of a single SC dose of…
- Trial name
- NCT05429073
- Testing
- RGLS8429
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Regulus Therapeutics Inc.
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A Possible Founding PKD2 Mutation Associated With Variable Phenotypes of ADPKD in Bergamo Province
This is an observational study aimed at assessing if a new and specific heterozygous deletion detected at PKD2 gene is associated to a "founder effect" in 10 Autosomal dominant polycystic kidney disease (ADPKD) patients, and at…
- Trial name
- POPULAR (NCT06594367)
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Polycystic Kidney Diseases, Polycystic Liver Disease
The Association Between Skeletal Muscle Mass and Severity of Polycystic Liver Disease and Polycystic Kidney Disease
Primary sarcopenia is used to describe aging and progressed with the physiologic decline. Secondary sarcopenia is associated many chronic disease, including acquired immune deficiency syndrome, cancer, chronic heart failure…
- Conditions
- Polycystic Kidney Diseases, Polycystic Liver Disease, Muscle Loss
- Trial name
- NCT05215964
- Testing
- Renal artery embolization
- Where
- Taiwan
- Volunteers
- 600 people
- Sponsor
- National Taiwan University Hospital
Autosomal Dominant Polycystic Kidney Disease
Role of ROS and cAMP-PKA Biomarkers in ADPKD
The primary objective is to determine the prognostic value of markers of ROS and cAMP-PKA signaling to assess disease severity and progression in patients with ADPKD.
- Trial name
- NCT07217158
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Polycystic Kidney, Autosomal Dominant
Feasibility Study of Metformin Therapy in ADPKD
This study is being done to determine if treatment with metformin, a drug widely used for the treatment of diabetes type 2, is safe and well tolerated by individuals with Autosomal Dominant Polycystic Kidney Disease (ADPKD) who…
- Trial name
- NCT02903511
- Testing
- Metformin
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of Colorado, Denver
Polycystic Kidney, Autosomal Dominant
Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
The investigator proposes a pilot randomized clinical trial to determine the safety and tolerability of empagliflozin in ADPKD patients.
- Trial name
- NCT05510115
- Testing
- Empagliflozin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Colorado, Denver
Autosomal Dominant Polycystic Kidney Disease, ADPKD
A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
Primary Objectives To assess the safety and tolerability of RGLS8429 To assess the impact of RGLS8429 on ADPKD biomarkers Secondary Objectives To assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV) To…
- Conditions
- Autosomal Dominant Polycystic Kidney Disease, ADPKD, Polycystic Kidney, Autosomal Dominant
- Trial name
- NCT05521191
- Testing
- RGLS8429
- Where
- 21 sites in United States
- Volunteers
- 68 people
- Sponsor
- Regulus Therapeutics Inc.
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Polycystic Kidney Diseases
Outcome of Autosomal Dominant Polycystic Kidney Disease Patients on Peritoneal Dialysis: a National Retrospective Study Based on Two French Registries (the French Language Peritoneal Dialysis Registry and the French Renal Epidemiology and Information Network).
Pathological features of Autosomal Dominant Polycystic Kidney disease (ADPKD) include enlarged kidney volume, a higher frequency of digestive diverticulitis and abdominal wall hernias.
- Trial name
- ADPKDPD (NCT03948113)
- Testing
- Dialysis
- Where
- France
- Volunteers
- 17,350 people, healthy volunteers welcome
- Sponsor
- CHU de Reims
Autosomal Dominant Polycystic Kidney Disease
Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency
The general aim of the trial is to assess the efficacy of one year treatment with long-acting somatostatin analogue (Octreotide LAR) compared with placebo in slowing kidney and liver growth rate in patients with ADPKD and…
- Trial name
- ALADIN2 (NCT01377246)
- Testing
- Octreotide-LAR, Saline solution.
- Where
- 6 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Polycystic Kidney Disease
PKD Clinical and Translational Core Study
Advances in our understanding of the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD) have opened up possibilities of new therapies to prevent disease progression.
- Trial name
- NCT01873235
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- University of Maryland, Baltimore